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Abstract
Background: Novel tuberculosis vaccines should be safe, immunogenic, and
effective in various population groups, including HIV-infected individuals. In this
phase II multi-centre, double-blind, placebo-controlled trial, the safety and
immunogenicity of the novel H1/IC31 vaccine, a fusion protein of Ag85B-ESAT-6
(H1) formulated with the adjuvant IC31, was evaluated in HIV-infected adults.
Methods: HIV-infected adults with CD4+ T cell counts .350/mm3 and without
evidence of active tuberculosis were enrolled and followed until day 182. H1/IC31
vaccine or placebo was randomly allocated in a 5:1 ratio. The vaccine was
administered intramuscularly at day 0 and 56. Safety assessment was based on
medical history, clinical examinations, and blood and urine testing. Immunogenicity
was determined by a short-term whole blood intracellular cytokine staining assay.
Results: 47 of the 48 randomised participants completed both vaccinations. In
total, 459 mild or moderate and 2 severe adverse events were reported. There were
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three serious adverse events in two vaccinees classified as not related to the
investigational product. Local injection site reactions were more common in H1/
IC31 versus placebo recipients (65.0% vs. 12.5%, p50.015). Solicited systemic
and unsolicited adverse events were similar by study arm. The baseline CD4+ Tcell
count and HIV viral load were similar by study arm and remained constant over
time. The H1/IC31 vaccine induced a persistent Th1-immune response with
predominately TNF-a and IL-2 co-expressing CD4+ T cells, as well as
polyfunctional IFN-c, TNF-a and IL-2 expressing CD4+ T cells.
Conclusion: H1/IC31 was well tolerated and safe in HIV-infected adults with a
CD4+ Lymphocyte count greater than 350 cells/mm3. The vaccine did not have an
effect on CD4+ T cell count or HIV-1 viral load. H1/IC31 induced a specific and
durable Th1 immune response.
Trial registration: Pan African Clinical Trials Registry (PACTR)
PACTR201105000289276
Introduction
Tuberculosis (TB) remains a global public health problem. One third of
humankind is infected with Mycobacterium tuberculosis (M.tb), which according
to the World Health Organization (WHO) led to almost 8.6 million new active TB
cases and 1.3 million TB deaths in 2012 [1]. Mycobacterium bovis Bacille Calmette-
Gue´rin (BCG), the only currently licensed TB vaccine, is effective in preventing
severe progressive disease in children but has limited impact on adult pulmonary
TB, the driving force of the TB global pandemic [2] [3]. Consequently, there is an
urgent need to develop safe and effective TB vaccines to accelerate progress
towards TB elimination.
Vaccination campaigns may administer TB vaccines to persons without
knowing their HIV status. It is therefore essential to evaluate the safety and
immunogenicity of TB vaccines in HIV-infected persons. Furthermore, HIV-
infected individuals have an increased risk of developing active TB, which may be
decreased by an effective TB vaccine that reduces the risk of reactivation of latent
TB infection (LTBI) or prevents TB infection or reinfection.
The Statens Serum Institut Hybrid (H1) recombinant fusion protein (antigen
(Ag)85B- Early Secretory Antigenic Target (ESAT)-6) TB vaccine, adjuvanted with
IC31, has been shown to be safe and immunogenic in BCG unvaccinated, TB
uninfected participants and in BCG vaccinated and latently TB infected
participants [4] In this phase II trial we evaluated the safety and immunogenicity
of H1/IC31administered to HIV-infected adults with CD4+ lymphocyte counts
greater than 350 cells/mm3 and without evidence of active TB disease (PACTR
Identifier: PACTR201105000289276).
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Methods
Regulatory approval
The study was conducted in accordance with the Helsinki Declaration and Good
Clinical Practice (GCP) and approved by the following local and national ethics
committees and regulatory authorities: Medical Research Coordinating
Committee of Tanzania, Institutional Review Board of the Ifakara Health
Institute, Tanzanian Food and Drug Authority, South African Medicines Control
Council and the Human Research Ethics Committee, University of
Witwatersrand.
Study design and sites
This was a phase II, multicentre, double-blind, randomized, placebo-controlled
trial. Participants were eligible if they were between 18 and 55 years of age, HIV
infected with CD4+ lymphocyte counts greater than 350/mm3, antiretroviral
therapy nai¨ve, generally healthy, had no evidence of active TB, had no history of
receiving immunosuppressive medication, immunoglobulins, blood products or
known hypersensitivity to any of the vaccine components. Women of child
bearing potential were eligible if pregnancy was excluded and they agreed to use at
least two forms of acceptable contraception from 21 days prior to administration
of the study vaccine through to the end of the study.
The trial took place at two African research facilities, the rural Bagamoyo Site of
the Ifakara Health Institute in Tanzania and the urban Tembisa Site of the Aurum
Institute in South Africa. It was carried out between 19th of December 2011 (first
participant first visit) and 10th of September 2012 (last participant last visit); the
first participant last visit was on the 2nd of July 2012. Written informed consent
was obtained from all literate patients. In case of illiteracy, informed oral consent
was attested by an impartial witness and documented with the patient’s
fingerprint according to ICH GCP guidelines (E6 (R1); 4.8.9), as approved by the
above mentioned ethics committees and regulatory authorities. The protocol for
this trial and CONSORT checklist are available as supporting information; see S1
Protocol and S1 Checklist.
Randomisation and blinding
Participants were randomly allocated in a 5:1 ratio to receive either H1/IC31
vaccine or placebo according to a computer-generated randomisation list. The
pharmacist prepared the vaccination according the pre-prepared study rando-
misation list. The unequal randomisation was employed to maximise exposure to
the H1/IC31 vaccine thereby increasing the chance of detecting a serious adverse
event to the vaccine. The study monitors, investigators, and participants were
blinded to study product. The study pharmacists prepared the investigational
product. Syringes were masked with red tape in order to conceal a slight difference
in the appearance of the H1/IC31 and placebo.
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Investigational product and vaccination
The Hybrid 1 (H1) vaccine is a recombinant fusion protein of the antigens Ag85B
and ESAT-6 (Ag85B–ESAT-6), developed and manufactured by the Statens Serum
Institut (Denmark). The adjuvant IC31 was developed by Intercell AG (Austria)
and consists the cationic polyaminoacid KLK, which is composed of the amino
acids lysine (K) and leucine (L), and ODN1a, a single stranded oligodeoxynu-
cleotide with alternating sequences of the nucleic acids inosine and cytidine. A
volume of 0.5 mL was administered providing a dose of 50 mg Ag85B-ESAT6
(antigen) and 500 nmol KLK +20 nmol ODN1a (adjuvant) or 0.5 mL Tris buffer
(placebo).
The H1/IC31 vaccine or placebo was administered intramuscularly with a 22 to
25-gauge needle at study day 0 and 56, after confirming eligibility criteria. The
first injection was given into the right and the second into the left deltoid muscle.
Safety
All solicited local (pain, tenderness, erythema, induration, nodules) and systemic
adverse events (AEs) (malaise, myalgia, headache, nausea, vomiting, athralgia,
fatigue, chills, fever) and unsolicited AEs were coded by the Aurum Institute
according to the MedDRA Dictionary Version 15.1. AEs and laboratory measures
of safety were graded using the Division of AIDS Table for Grading the Severity of
Adult and Pediatric Adverse Events (version 1.0, 2004) as mild, moderate, severe
or potentially life-threatening and assessed for their relationship to study product.
CD4+ T cell count and HIV-1 viral load were measured pre and 14 days post
vaccination and at the study end.
IFN-c release assay
QuantiFERON-TB Gold In-Tube assay (QFT) (Celestis) was performed at
screening and at day 182 to identify whether H1/IC31 induced a false positive
result. The assay was carried out according to manufacturer’s instructions with a
cut-off value of 0.35 IU IFN-c/mL to either antigen (ESAT-6/CFP-10).
Immunological assays
All immunological assays described below were performed by the South African
TB Vaccine Initiative (SATVI) laboratory in Cape Town, South Africa.
The whole blood intracellular cytokine staining assay was used to quantify
antigen specific CD4+ and CD8+ T cell responses (interferon-gamma (IFN-c),
tumour necrosis factor-alpha (TNF-a), interleukin (IL)-2 and IL-17) after
stimulation with peptide pools of Ag85B and ESAT-6 peptides (each consisting of
15-mer peptides, overlapping by 10 amino acids, final concentration of 2 mg/mL,
GenScript) and recombinant H1 fusion protein (final concentration of 5 mg/mL,
Satens Serum Institute). CD4+ and CD8+ T cell expression of IFN-c, TNF-a and
IL-2 was measured to assess the polyfunctional characteristics of H1/IC31 induced
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T cells. The primary immunogenicity endpoint was assessed at day 70 (14 days
post 2nd vaccination).
Processing of whole blood started within 75 minutes after phlebotomy. One mL
whole blood from each study participant and time point were either left
unstimulated (negative control) or stimulated with peptide pools of Ag85B,
ESAT-6, the H1 fusion protein and phytohemagglutinin (PHA) (positive
controls). The co-stimulatory antibodies anti-CD28 and anti-CD49d (BD
Biosciences, at 0.5 mg/mL each) were included in all assay conditions. The whole
blood was incubated at 37 C˚ for 7 hours and Brefeldin-A (Sigma-Aldrich, 10 mg/
mL) was added thereafter. The blood sample was transferred to a waterbath at
37 C˚ and incubated for a further 5 hours. Thereafter the waterbath was switched
off and allowed to reach room temperature. Within the following 10 hours the
blood was harvested with EDTA (Sigma-Aldrich, at 1.8 mM), red blood cells were
lysed and white cells fixed with 9 ml of FACS lysing solution (BD Biosciences).
Thereafter, white cells were pelleted and cryopreserved in cryosolution containing
50% RPMI (Lonza), 40% fetal calf serum (BioWest) and 10% DMSO (Sigma-
Aldrich). The specimens were shipped to SATVI ensuring that the cold chain was
maintained.
The subsequent intracellular cytokine staining (ICS) procedure was performed
as follows: the stimulated, fixed and frozen white cells from whole blood were
thawed in a water bath at 37 C˚. The thawed cells were transferred to labelled tubes
containing phosphate buffered saline (PBS, BioWhittaker) and washed. Next, the
cells were permeabilised using Perm/Wash solution (BD Biosciences). Cells were
then stained with the following anti-human antibodies: CD3 BV421 (BD
Biosciences, MOPC-21), CD4-QDot605 (Invitrogen, S3.5), CD8-Cy5.5PerCP (BD
Biosciences, SK1), CCR7-PE (eBioscience, 150503), IFN-c-Alexa 700 (BD
Biosciences, B27), TNF-a-Cy7PE (eBioscience, Mb11), IL-2-FITC (BD
Biosciences, 5344.111), IL-17-Alexa 647 (eBioscience, SCPL1362) and CD45RA
BV 570 (eBioscience, H1100). Results of CCR7 and CD45RA staining are not
presented here. Samples were stained, acquired and analysed in batches. For every
ICS assay experiment, compensation controls (single stained positive and negative
mouse kappa compensation beads) were included. These controls were processed
in parallel with the study samples during the staining and acquisition process to
allow post acquisition flow cytometry data compensation. After the samples were
acquired on the BD LSRII cytometer (BD Biosciences, San Jose, CA), flow analysis
was performed using FlowJo software (TreeStar version 9.6.2).
Anti-Ag85B-ESAT-6 specific IgG antibody assay was used to measure
antibodies specific to antigens of H1/IC31 as an indicator of humoral reactivity.
Plasma was collected and frozen from ex vivo whole blood.
IFN-c EliSpot assay
Prior to the start of the study both sites laboratories were trained on specimen
processing and storage. Both sites passed their proficiency tests for PBMCs cell
viability and number and were IATA certified for shipping specimens. IFN-c
EliSpot assay was not possible to conduct on PBMCs collected from the Tembisa
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site because the cell recovery upon thaw was too low (less than 100,000 cells). The
cell recovery and yield was excellent for PBMCs from Bagamoyo. However, on
Elispot assay, these PBMCs showed high level of spot forming units in the negative
control wells that was indistinguishable from the response detected with the
assay’s positive control (stimulation with PHA). Therefore, we could not reliably
report the IFN-c EliSpot assay results.
Statistical considerations
A sample size of 40 vaccine and 8 placebo recipients was adequate to assess the
safety and immunogenicity of the vaccine. Assuming an incidence of adverse
events in the vaccine and placebo arm of 10 and 15 per 100 person years, the
probability of observing at least one adverse event was 0.87 and 0.95, respectively.
The sample size for immunogenicity response rates were based on the phase I
study results where 100% responded by the 2nd vaccination. The sample size was
adequate to show an immune response in 70–90% of vaccine recipients and an
absolute difference of 66% in the proportion of vaccine and placebo recipients
with an immune response with 90% power.
Laboratory and immunogenicity parameters were summarised by study arm
and visit. The baseline is defined as the measurement at day 0. Comparing
cytokine responses (magnitude of response using all participants) between study
arms was conducted using the Wilcoxon rank-sum test and between time points
using the Wilcoxon signed-ranks test. The CD4 and log10(HIV-1 viral load)
change over follow-up was estimated for each individual using linear regression
and the estimated slopes compared by study arm using the Wilcoxon rank-sum
test. All AEs were summarised by system organ class and preferred term by
treatment group and visit. The statistical analysis was performed using software
STATA version 13.0.
The study protocol and the CONSORT checklist are available as supporting
information.
Results
Study population
In total, 167 adults were screened and 48 volunteers were enrolled (24 in Tanzania
and South Africa respectively); 47 participants completed both vaccinations. The
CONSORT diagram is shown in Fig. 1. Participants in the H1/IC31, versus
placebo, arm were older (median age 35 vs 29.5 years, respectively) and less likely
to be female (52.5% vs 75%, respectively) (Table 1). The overall proportion of
self-reported BCG vaccination was 81.3%, similar by study arm. The median
CD4+ T cell count, viral load and other baseline characteristics were similar by
study arm (Table 1).
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Safety and reactogenicity
The safety analysis included data from both study sites. In total 461 AEs were
reported (Table 2).
H1/IC31 versus placebo recipients were more likely to have one or more local
injection site AE (H1/IC31:26/40 (65.0%), placebo: 1/8 (12.5%), p50.015). The
local AEs in the H1/IC31 arm were graded as mild (55/62, 88.7%) or moderate (7/
62, 11.3%) and were either not related (1/62, 1.6%), possibly (23/62, 37.1%),
probably (37/62, 59.7%) or (1/62, 1.6%) definitely related. In the H1/IC31 arm,
the most frequent solicited local AEs were pain (21/62, 33.9%) and induration
Fig. 1. CONSORT diagram of subjects for screening, exclusions, randomisation, vaccination and follow-up in the vaccine trial.
doi:10.1371/journal.pone.0114602.g001
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(20/62, 32.3%). The one local AE in the placebo arm was assessed as mild and
probably related.
29/40 (72.5%) of H1/IC31 participants experienced a total of 84 solicited
systemic AEs, which were graded as mild (72/84, 85.7%) or moderate (12/84,
14.3%) and 51.2% (43/84) and 22.6% (19/84) were assessed as possibly or
probably related respectively. In the placebo arm, 7/8 (87.5%) participants
experienced a total of 17 systemic AEs. These were graded as mild (17/17, 100%)
and either unrelated (4/17, 23.5%) or possibly related (13/17, 76.5%). In the H1/
IC31 and placebo arms, headache (23/84, 27.4%; 4/17, 23.5%) and fatigue (22/84,
26.2%; 3/17, 17.6%) were the most common solicited systemic AEs. The
percentage of patients with at least one solicited systemic AE was similar by study
arm (H1/IC31 29/40 [72.5%] vs placebo 7/8 [87.5%]; p50.4).
All participants reported one or more unsolicited systemic AE (297 in total).
The 40 H1/IC31 recipients experienced 251 unsolicited AEs, which were graded as
either mild (215/251, 85.7%), moderate (33/251, 13.2%) of severe (2/251, 0.8%),
and one AE was ungraded (pregnancy). Of the 251 unsolicited AEs among H1/
IC31 recipients, 152 (60.6%) were not related, 96 (38.3%) were possibly related
and 3 (1.2%) were probably related. 46 unsolicited AEs were reported in the
placebo group, all considered unrelated (34/46, 73.9%) or possibly related (12/46,
26.1%) and graded as either mild (40/46, 87%) or moderate (6/46, 13%). There
were three serious individual case safety reports from two H1/IC31 participants,
all classified as unrelated to the investigational product. One participant had two
separate hospitalisations for malaria and drainage of a perianal abscess. The
second participant delivered a premature baby that died as a result of respiratory
failure. The participant had a history of one miscarriage in the last trimester and
one delivery of another child, who died soon after birth. In the H1/IC31 and
placebo arms, unsolicited systemic AE were most frequently categorised as blood
and lymphatic disorders (48/251, 19.1%; 12/46, 26.1%) or infections and
infestations (44/251, 17.5%; 10/46, 21.7%).
Table 1. Demographic and baseline characteristics of the study participants by vaccination group.
Variable Placebo H1/IC31
(n58) (n540)
Age Median (IQR) 29.5 (28–41) 35 (30.5–41.5)
Gender Female n (%) 6 (75.0) 21 (52.5)
Ethnic group* Black n (%) 8 (100) 40 (100)
Body Mass Index Median (IQR) 23.1 (20.2–27.0) 23.8 (20.3–30.8)
BCG vaccination (self-report) Yes n (%) 6 (75.0) 33 (82.5)
CD4# (cells/uL) Median (IQR) 556.5 (464–708) 620.5 (475–725)
Viral load# (cp/mL) Median (IQR) 17887 (544, 43297) 16968 (2228, 42547)
*other groups included Indian, White, Asian or mixed heritage.
#based on arithmetic mean of participant data from the two screening visits and day 0.
#based on arithmetic mean of participant data from the first screening visit and day 0.
IQR interquartile range.
doi:10.1371/journal.pone.0114602.t001
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The frequencies of one or more local and systemic solicited AE per participant
was similar after the first and the second vaccination with H1/IC31 (solicited
local: 50% vs 32.5%, p50.18; solicited systemic: 60% vs 50%, p50.25), while
unsolicited AEs were less frequent after the second H1/IC31 vaccination (97.5% vs
80%, p50.007).
QFT positive, versus negative, H1/IC31 recipients had more solicited local
reactions (82.3% vs 47.8%, p50.046), but not solicited systemic (82.3% vs 65.2%,
p50.3) or unsolicited AEs (100% vs 100%).
There were no significant differences in haematology, biochemistry or urinalysis
test results at any visit by study arm. The median CD4 slope (per day) over the
182 day follow-up period was 20.86 and 20.59 cells per ml in the H1/IC31 and
placebo arms, respectively, indicating no difference by study arm (p50.85). The
median log10 (HIV-1 viral load) slope per day (median 22.961024 and
Table 2. Adverse events (AEs) during trial period (day 0–182) by vaccination group.
Placebo H1/IC31
n58 n540
All grades Grade $3 All grades Grade $3
Solicited local AEs
Any 1 0 62 0
Pain 0 0 21 0
Tenderness 0 0 10 0
Erythema 0 0 9 0
Induration 1 0 20 0
Nodules 0 0 2 0
Solicited systemic AEs
Any 17 0 84 0
Malaise 0 0 2 0
Myalgia 4 0 15 0
Headache 4 0 23 0
Nausea 2 0 0 0
Vomiting 0 0 1 0
Arthralgia 1 0 15 0
Fatigue 3 0 22 0
Chills 2 0 2 0
Fever 1 0 4 0
Unsolicited AEs
Any 46 0 251 2*
Blood/lymphatic disorders 12 0 48 0
Infections and infestations 10 0 44 0
Renal/urinary disorders 2 0 28 0
Other AEs 22 0 131 2*
TOTAL 64 0 397 2*
*reported as possibly related.
doi:10.1371/journal.pone.0114602.t002
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20.5461024 copies/ml in the H1/IC31 arm and placebo arms, respectively) was
also similar by study arm (p50.93).
QuantiFERON status
At baseline, 17/40 (42.5%) of the H1/IC31 and 3/8 (37.5%) of the placebo
participants and participants had a positive QFT result. Conversion from QFT
negative to QFT positive was observed in 8 of the 23 (34.8%) H1/IC31 recipients,
and in none of the placebo recipients. Two of the 17 QFT positive H1/IC31
participants (11.8%) converted to QFT negative by day 182. One initially QFT
positive placebo recipient (33.3%) was QFT negative after 182 days. 10 QFT
results from 9 H1/IC31 and 1 placebo recipient were missing at day 182 (Table 3).
Immunogenicity
Only samples from the 24 participants from the Bagamoyo Site were used for the
immunogenicity analysis. None of the whole blood intracellular cytokine assay
specimens from the Tembisa site were useable, as they thawed as a result of the
liquid nitrogen tank in which they were stored running dry. The gating strategy
for flow cytometry analysis is shown is shown in Fig. 2.
Among H1/IC31 recipients, the median magnitude of CD4+ T cells expressing
one or more cytokines (IFN-c and/or IL-2 and/or TNF-a) in response to Ag85B,
ESAT-6 and H1 were greatest two weeks after the second vaccination (day 70),
and remained elevated compared with baseline up to day 182 (Fig. 3). The
greatest CD4+ T cell responses were observed after stimulation with H1 (Fig. 3). A
similar kinetics of response was seen for CD4+ T cell expressing either IFN-c, IL-2
or TNF-a in response to H1, and there were no significant IL-17 responses
(Fig. 4). Among H1/IC31 recipients the magnitude of CD8+ T cells responses to
Ag85B, ESAT-6 and H1 did not exceed pre-vaccination levels two weeks after the
second vaccination (Fig. 3).
Among H1/IC31 recipients, the median CD4+ T cell IFN-c and/or IL-2 and/or
TNF-a responses to H1 two weeks post second vaccination (day 70) did not differ
by baseline CD4 count (CD4 count,500:0.34%, $500:0.38%, p50.9), or by QFT
status (QFT positive: 0.39%, negative 0.38%, p50.5, Fig. 5a and 5b).
The functional capacity of the CD4+ T cells was assessed in the 7 possible cell
subsets producing any combination of the IFN-c, TNF-a or IL-2 in response to
H1 stimulation at day 0, 14, 56, 70 and 182 (Fig. 6). Most reactive CD4+ T cells
expressed IFN-c, TNF-a and IL-2 or TNF-a and IL-2 in response to H1 with a
minimum at day 0, a maximum at day 70 and elevated levels at day 182. Single
cytokine producing CD4+ T cells most commonly produced IL-2 in response to
H1.
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Humoral response determined by Anti-Ag85B-ESAT-6 specific IgG
antibody assay
There was no difference in IgG levels by study arms two week post second
vaccination (day 70) and 182 (data not shown).
Discussion
This is the first report on safety and immunogenicity of the H1/IC31 subunit TB
vaccine administered to HIV-infected adults with CD4+ lymphocyte counts .350
cells/mm3. Key findings are: (i) H1/IC31 was safe and well tolerated; (ii) H1/IC31
did not have a negative impact on CD4+ T cell count or on HIV-1 viral load. (iii)
H1/IC31 induced a strong, specific and long lasting, CD4+ T cell response; (iv)
H1/IC31 vaccination induced primarily triple (IFN-c, TNF-a and IL-2) or double
(TNF-a and IL-2) positive CD4+ T cells.
There is a concern that in HIV-infected individuals, TB vaccines may promote
immune activation leading to increased adverse events and progression of HIV.
Vaccination with Modified Vaccinia Ankara virus expressing antigen 85A
(MVA85A) [6] [7] [8] and inactivated M. vaccae [9] [10] in HIV-infected persons
had favourable safety profiles. RUTI vaccination (heat killed M.tb, fragmented) of
HIV-infected adults was associated with an increased risk of local reactions,
including nodules and sterile abscesses [11]. In our study, H1/IC31 vaccination in
HIV-infected individuals was tolerable and had a safety profile similar to that seen
among H1/IC31 vaccinated, HIV-uninfected, mycobacterially-nai¨ve, BCG vacci-
nated and latently TB-infected individuals in Europe [4][5]. In the present study,
there was no major change in CD4+ T cell count and HIV-1 viral load trends,
similar to reports on vaccination with MVA85A [6] [7] and Aeras 402 [12].
TB vaccines in HIV-infected individuals potentially may be less immunogenic
due to HIV-associated immunosuppression. H1/IC31 vaccination of HIV-infected
participants with a high CD4 count (.350 cells/mm3) induced a specific Th1-type
response to the H1 antigen, and its Ag85B and ESAT-6 subunits. We observed
some CD4+ T cell IFN-c responses to the vaccine antigen H1 at enrolment - prior
to vaccination. The responses were most prominent in the QFT positive
individuals, and probably due to latent TB infections or possibly cross reacting
environmental mycobacterial infections. Despite these baseline responses, H1/
Table 3. QuantiFERON status at baseline and at day 182.
Vaccination group Study day n PositiveN (%) NegativeN (%) QuantiFERON conversion
Negative to
Positive
Positive to
Negative
Placebo Baseline 8 3 (37.5) 5 (62.5) 0 1
Day 182 7 1 (14.3) 6 (85.7)
H1/IC31 Baseline 40 17 (42.5) 23 (57.5) 8 2
Day 182 31 17 (54.8) 14 (45.2)
doi:10.1371/journal.pone.0114602.t003
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IC31 vaccination induced significantly higher CD4+ T cell responses that were
durable. These results are encouraging and suggest that latent TB infection will
not mask an H1/IC31 specific immune response. The magnitude and durability of
the Th1 responses in HIV-infected participants, and the lack of humoral response,
has similarly been observed in HIV-uninfected participants [4] [5].
In our study, H1/IC31 induced predominately TNF-a/IL-2 and IFN-c/TNF-a/
IL-2 co-expressing CD4+ T cells with a peak two weeks after the second
Fig. 2. Gating strategy used for flow cytometric analysis of H1-induced Tcell cytokine expression. The plots show sequentially the gating hierarchy of
one representative sample: CD3+ Tcells, single cells, lymphocytes, time, CD8-T cells, which were further gated for CD4+ cells. The plots on the lowest row
include the cytokine expression gates for either unstimulated or H1 fusion protein stimulated PBMC at day 70 divided in the co-expression of IL-17 and IL-2
or TNF-a and IFN-c by CD4+ T cells.
doi:10.1371/journal.pone.0114602.g002
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vaccination which remained elevated for up to 6 months. Both cell subsets, in
particular the TNF-a/IL-2 double positive subset, have been found to include a
high proportion of central memory T cells [13] [14] and to be less differentiated
[15], more long lived [15] [16] and functionally superior [17] to IFN-c single
cytokine expressing T cells. The protective role of polyfunctional CD4+ T cells
against tuberculosis infection is still debated. However, several studies have
observed a positive correlation between protection against disease and induced T
cell polyfunctionality, particularly those expressing IL-2, which is associated with
long-term persistence of primed CD4+ T cells in vivo [14] [18] [19] [20] [21]. The
TNF-a/IL-2 central memory T cell population may be of particular relevance for
the activity of these vaccines. In a recent murine study TNF-a/IL-2 central
memory T cells were implicated in the long-term control of chronic TB infection
[22]. This predominance of the TNF-a/IL-2 subset seems to be characteristic for
the IC31 and CAF01 adjuvant. In comparison, the MVA85A, M72/AS01 and M72/
Fig. 3. Kinetics of Ag85B, ESAT-6 and H1 specific CD4+ and CD8+ T cells expressing IFN-c, TNF-a or IL-2 for day 0 for the placebo arm (P: day 0)
and over a 6-month period (day 0–182) in the vaccine (H1/IC31) arm detected by a short-term whole blood intracellular cytokine assay.
doi:10.1371/journal.pone.0114602.g003
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AS02 vaccines primarily induced polyfunctional IFN-c/TNF-a/IL-2 CD4+ T cells
[23] [24], while Aeras 402 induced both polyfunctional CD4+ and CD8+ T cells
[25].
The role of Th17 cells producing IL-17 is the subject of ongoing debate. Reports
suggest that IL-17 producing T cells support a balanced immune response
improving the protective efficacy of novel vaccines [24] [26]. In our study, H1/
IC31 induced IL-17 mono- or co-expressing CD4+ T cells that were barely
detectable post vaccination and contrasts with MVA85A which induced IL-17
producing T cells [24].
H1/IC31 vaccine induced poor CD8+ T cell responses, which has likewise been
described for other vaccine candidates [6] [23]. These findings may be explained
by methodological issues of the ex vivo assay system, such as the possible
suboptimal length of the peptides used in the assay (15 amino acids) or an
inadequate limit of detection [6] [23].
Fig. 4. Kinetics of IFN-c, TNF-a, IL-2 and IL-17 expressing CD4+ T cells after stimulation with H1 over a 6-month period (day 0–182) in the H1/IC31
vaccination group detected by a short-term whole blood intracellular cytokine assay. Footnote: sample size for all measurements at days 0, 14 and 56
was n520 and for day 70 and 182 was n519.
doi:10.1371/journal.pone.0114602.g004
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As formerly reported, H1/IC31 vaccination can lead to conversion of the QFT
result because of its ESAT-6 component [4] [5]. In our study, this phenomenon
occurred in one third of initially QFT negative participants. However, reversions
suggest that some of the observation might also be attributed to within-subject
Fig. 5. Frequencies of H1 specific CD4+ T cells expressing IFN-c, TNF-a or IL-2 at day 0, 14, 56, 70 and 182, for vaccination group H1/IC31 group
[unstimulated frequencies have been subtracted] for a) QFT positive n56 and b) QFT negative n514. Footnote: comparison of CD4+ Tcell IFN-c and/
or IL-2 and/or TNF-a responses to H1 at day 70 by those QFT positive or negative, p50.5.
doi:10.1371/journal.pone.0114602.g005
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variability of the QFT assay [27]. The concern that H1/IC31 can interfere with
IFN-c release assays (IGRA) such as QFT for detection of LTBI has becomes less
important since the WHO does not recommend IGRA to replace tuberculin skin
tests in resource-constrained settings [28], where the vaccine would be broadly
used. Furthermore, new tests using diagnostic markers other than ESAT-6 for
disease screening are under development and have the potential to eliminate the
issue of interference with the vaccine for low- and high-burden countries [29].
New subunit TB vaccines should boost the efficacy of BCG and prevent TB
infection and prevent latent TB infection from progressing to active disease. Both
mechanisms are essential for the control of the TB epidemic. In order to achieve a
better post-exposure protection, the Statens Serum Institut has added a latency-
associated antigen (Rv2660c) to the H1/IC31 backbone, to create a multistage
Fig. 6. Frequencies of H1 specific CD4+ T cells expressing any combination of IFN-c, TNF-a and IL-2 at day 0, 14, 56, 70 and 182 in the vaccination
group [unstimulated frequencies have been subtracted].
doi:10.1371/journal.pone.0114602.g006
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vaccine, H56 (Ag85B-ESAT-6-Rv2660c) [30]. Our trial of H1/IC31 provides
valuable information to support the clinical development of the novel multistage
vaccine H56. Particularly important is that H1/IC31 induces multifunctional T
cells expressing TNF-a and IL-2, markers of central memory T cells, which are
required for long-term protection against both reactivation and infection [22].
This is critical for the vaccination of vulnerable populations such as HIV-infected
individuals who often have a high level of exposure to TB and a relatively high
prevalence of latent TB infection. Inevitably, the multistage H56 vaccine should
also be evaluated in HIV-infected individuals to ensure that it confers durable
immune protection in this target group.
The present study had a number of limitations. The study was not powered to
show difference between subgroups, particularly by baseline QFT status. The
whole blood intracellular cytokine staining data from one site and IFN-c EliSpot
assay data from both sites did not meet the internal quality control standards,
which limits comparability to other TB vaccine trials. The restriction to HIV-
infected individuals with CD4+ lymphocyte counts greater than 350 cells/mm3
was necessary because of safety concerns, but limits the generalizability of the
results.
In conclusion, the intramuscular injection of the adjuvanted TB subunit
vaccine H1/IC31 was safe and immunogenic in HIV-infected adults, with CD4+
lymphocyte counts greater than 350 cells/mm3, from TB endemic areas.
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